116 related articles for article (PubMed ID: 23350355)
1. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.
Auzenne EJ; Klostergaard J; Mandal PK; Liao WS; Lu Z; Gao F; Bast RC; Robertson FM; McMurray JS
J Exp Ther Oncol; 2012; 10(2):155-62. PubMed ID: 23350355
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3.
Mandal PK; Liao WS; McMurray JS
Org Lett; 2009 Aug; 11(15):3394-7. PubMed ID: 19594124
[TBL] [Abstract][Full Text] [Related]
3. Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors.
Cerulli RA; Shehaj L; Tosic I; Jiang K; Wang J; Frank DA; Kritzer JA
Bioorg Med Chem; 2020 Jun; 28(12):115542. PubMed ID: 32503696
[TBL] [Abstract][Full Text] [Related]
4. Pro-Nifuroxazide Self-Assembly Leads to Triggerable Nanomedicine for Anti-cancer Therapy.
Misra SK; Wu Z; Ostadhossein F; Ye M; Boateng K; Schulten K; Tajkhorshid E; Pan D
ACS Appl Mater Interfaces; 2019 May; 11(20):18074-18089. PubMed ID: 31013055
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules.
Fletcher S; Page BD; Zhang X; Yue P; Li ZH; Sharmeen S; Singh J; Zhao W; Schimmer AD; Trudel S; Turkson J; Gunning PT
ChemMedChem; 2011 Aug; 6(8):1459-70. PubMed ID: 21618433
[TBL] [Abstract][Full Text] [Related]
6. Phospho-Ser727 triggers a multistep inactivation of STAT3 by rapid dissociation of pY705-SH2 through C-terminal tail modulation.
Yang J; Kunimoto H; Katayama B; Zhao H; Shiromizu T; Wang L; Ozawa T; Tomonaga T; Tsuruta D; Nakajima K
Int Immunol; 2020 Feb; 32(2):73-88. PubMed ID: 31555812
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.
Furtek SL; Matheson CJ; Backos DS; Reigan P
Oncotarget; 2016 Nov; 7(47):77998-78008. PubMed ID: 27793003
[TBL] [Abstract][Full Text] [Related]
8. Allosteric regulation in STAT3 interdomains is mediated by a rigid core: SH2 domain regulation by CCD in D170A variant.
Zhao T; Karki N; Zoltowski BD; Matthews DA
PLoS Comput Biol; 2022 Dec; 18(12):e1010794. PubMed ID: 36542668
[TBL] [Abstract][Full Text] [Related]
9. Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment.
Chen H; Bian A; Zhou W; Miao Y; Ye J; Li J; He P; Zhang Q; Sun Y; Sun Z; Ti C; Chen Y; Yi Z; Liu M
ACS Cent Sci; 2024 Mar; 10(3):579-594. PubMed ID: 38559310
[TBL] [Abstract][Full Text] [Related]
10. Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions.
Drewry JA; Fletcher S; Yue P; Marushchak D; Zhao W; Sharmeen S; Zhang X; Schimmer AD; Gradinaru C; Turkson J; Gunning PT
Chem Commun (Camb); 2010 Feb; 46(6):892-4. PubMed ID: 20107641
[TBL] [Abstract][Full Text] [Related]
11. Novel
Pan M; Kurtz J
Front Med (Lausanne); 2023; 10():1251088. PubMed ID: 38020118
[TBL] [Abstract][Full Text] [Related]
12. Role of STAT3 in cancer cell epithelial‑mesenchymal transition (Review).
Zhang G; Hou S; Li S; Wang Y; Cui W
Int J Oncol; 2024 May; 64(5):. PubMed ID: 38488027
[TBL] [Abstract][Full Text] [Related]
13. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.
Hu Y; Dong Z; Liu K
J Exp Clin Cancer Res; 2024 Jan; 43(1):23. PubMed ID: 38245798
[TBL] [Abstract][Full Text] [Related]
14. JAK-STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL.
Haselager MV; Thijssen R; Bax D; Both D; De Boer F; Mackay S; Dubois J; Mellink C; Kater AP; Eldering E
Mol Oncol; 2023 Jun; 17(6):1112-1128. PubMed ID: 36550750
[TBL] [Abstract][Full Text] [Related]
15. STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges.
Wong GL; Manore SG; Doheny DL; Lo HW
Semin Cancer Biol; 2022 Nov; 86(Pt 3):84-106. PubMed ID: 35995341
[TBL] [Abstract][Full Text] [Related]
16. Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology.
Zhou J; Wang L; Peng C; Peng F
Front Pharmacol; 2022; 13():886198. PubMed ID: 35784750
[TBL] [Abstract][Full Text] [Related]
17. Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review).
Yang R; Song Y; Shakoor K; Yi W; Peng C; Liu S
Mol Med Rep; 2022 May; 25(5):. PubMed ID: 35302174
[TBL] [Abstract][Full Text] [Related]
18. The JAK/STAT signaling pathway: from bench to clinic.
Hu X; Li J; Fu M; Zhao X; Wang W
Signal Transduct Target Ther; 2021 Nov; 6(1):402. PubMed ID: 34824210
[TBL] [Abstract][Full Text] [Related]
19. Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis.
Aftabizadeh M; Li YJ; Zhao Q; Zhang C; Ambaye N; Song J; Nagao T; Lahtz C; Fakih M; Ann DK; Yu H; Herrmann A
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33491667
[TBL] [Abstract][Full Text] [Related]
20. STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy.
Yang PL; Liu LX; Li EM; Xu LY
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32872659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
